Citing its impact on “health care insurance costs,” the Institute for Clinical and Economic Review has issued its dreaded insurance profitability “alert” for two new treatments for peanut allergies. ICER’s report encourages insurance companies to deny coverage and impose substantial barriers for patients seeking access to the treatments.
July is the month where we as a nation commemorate the Declaration of Independence of our country. On July 4, 1776 the Continental Congress declared that the thirteen American Colonies…
ICER uses quality-adjusted life years to calculate value and determine health care access. Here are 5 ways that the QALY formula is bad for patients.
The Institute for Clinical and Economic Review and its controversial “one-size-fits-all” value framework are a direct threat to patients living with rare diseases, an independent report warns.
To fix its broken value framework, ICER should stop using the QALY, or quality-adjusted life year, in its value framework and cost assessments.
Patients living with migraine need access to effective treatments. ICER has begun its process of evaluating treatments for acute migraine.
The Institute for Clinical and Economic Review (ICER) is floating a power grab at the Food and Drug Administration to deny patients access to innovation.
Thousands of young boys living with Duchenne Muscular Dystrophy, a rare and fatal disease, could be denied access to treatment, due to a new ICER report.
We have an important message for ICER: Patients are not a number. Patients living with depression and multiple sclerosis have the same right to access treatments as anyone else.
An obscure health care cost evaluator could deliver a devastating blow to patients living with multiple sclerosis this week, as it evaluates a promising new treatment for the autoimmune disorder.…